Navigating regulatory hurdles in the U.S. and Europe, plus fierce competition from rival Apellis, Astellas’ geographic ...

Chief Scientific Officer Yoshitsugu Shitaka, Ph.D., won’t be so lucky. Astellas intends to create the new role of chief ...

Not satisfied with simply changing personnel, Japanese drugmaker Astellas has announced a new management structure, effective ...

Astellas has changed its management structure, establishing new top management positions and making personnel changes. The goal of the change is to promote drug discovery activities swiftly and ...

Minds + Assembly, a 2024 MM+M Agency 100 honoree, added Chuck Hemann as chief integration officer and Jonathan Woodring as ...

Astellas is ready to launch its first digital ... The companies are now hoping to sell the platform to commercial health programmes in the US. The patient monitoring platform puts heart failure ...

Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that the following changes to its management structure effective April 1, 2025.

manufacturing and commercial capabilities. This agreement is another example of our commitment to delivering meaningful therapies for patients with genetic diseases.” In July 2023 Astellas ...